Last reviewed · How we verify
Bevacizumab and FOLFIRI
Bevacizumab and FOLFIRI is a VEGF inhibitor, chemotherapy Small molecule drug developed by Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente. It is currently in Phase 2 development for Metastatic colorectal cancer. Also known as: CPT11, Folinic acid, 5FU.
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor.
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor. Used for Metastatic colorectal cancer.
At a glance
| Generic name | Bevacizumab and FOLFIRI |
|---|---|
| Also known as | CPT11, Folinic acid, 5FU |
| Sponsor | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente |
| Drug class | VEGF inhibitor, chemotherapy |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptor and thus inhibiting the formation of new blood vessels that tumors need to grow. FOLFIRI, on the other hand, targets rapidly dividing cancer cells by inhibiting topoisomerase I, an enzyme involved in DNA replication.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Hypertension
- Diarrhea
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (PHASE1)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
- FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab and FOLFIRI CI brief — competitive landscape report
- Bevacizumab and FOLFIRI updates RSS · CI watch RSS
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente portfolio CI
Frequently asked questions about Bevacizumab and FOLFIRI
What is Bevacizumab and FOLFIRI?
How does Bevacizumab and FOLFIRI work?
What is Bevacizumab and FOLFIRI used for?
Who makes Bevacizumab and FOLFIRI?
Is Bevacizumab and FOLFIRI also known as anything else?
What drug class is Bevacizumab and FOLFIRI in?
What development phase is Bevacizumab and FOLFIRI in?
What are the side effects of Bevacizumab and FOLFIRI?
What does Bevacizumab and FOLFIRI target?
Related
- Drug class: All VEGF inhibitor, chemotherapy drugs
- Target: All drugs targeting VEGF-A
- Manufacturer: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Also known as: CPT11, Folinic acid, 5FU
- Compare: Bevacizumab and FOLFIRI vs similar drugs
- Pricing: Bevacizumab and FOLFIRI cost, discount & access